How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology and Vaccines

Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for...

READ MORE

Four Key Considerations to Help Prepare for the Next Public Health Threat

As a CDMO, Emergent has been working for more than two decades to develop, manufacture and deliver protections against public...

READ MORE

The Path to Reemergence

Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently shared his insights with Pharma...

READ MORE

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

  • Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...
READ MORE

Emergent Enters Into a New CDMO Agreement with Providence Therapeutics to Provide Fill/Finish Drug Product Manufacturing

Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing...

READ MORE

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021  Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. ...

READ MORE
WANT MORE INFORMATION?

Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below.  If you’re a media representative, please feel free to contact us at cdmo@ebsi.com.

Interested in learning more about Emergent BioSolutions, Inc.? Please visit emergentbiosolutions.com.

WANT MORE INFORMATION?

Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below.  If you’re a media representative, please feel free to contact us at mediarelations@ebsi.com.

Interested in learning more about Emergent BioSolutions, Inc.? Please visit emergentbiosolutions.com.